News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

PROTEXT MOBILITY, INC. (TXTM) AND RSAMMDA LLC (DELAWARE) PROVIDES SHAREHOLDER UPDATE

ProText Mobility, Inc.

Protext Mobility, Inc. (OTC PINK: TXTM) and RSAMMDA LLC (Delaware) (“RSAMMDA.LLC”) are pleased to provide the following shareholder update and announce an initial order for 2.33 million pounds of Genus Cannabis Sativa under a supply agreement. Dr. Ahmed Jamaloodeen (Dr.J), Protext Chairman commented, “This is a terrific milestone and demonstrates years of hard work and relentless pursuit of educating the masses and government collaboration. The initial order calls for the delivery of 2.33 million pounds of cannabis, arguably the largest single cannabis flower and biomass order in history to date post legalization. The specific strain we are growing for this order is Charlottes Angel for high percentage CBD flower and biomass. Everything we do is under South Africa federally issued permits, and license to import, export, grow hemp and cannabis from seed to sale, R & D, as well as develop and distribute our own brand of finished products. “Our proprietary, branded CBD product line and online marketplace is anticipated to launch shortly. Due to our early pioneering of hemp and cannabis as a massive community uplift opportunity in South Africa, we were approved as the first government sponsored pilot project that would enable proof of concept to other farms as a blueprint of this business model. This early blueprint is now a proven business model for South African farmers, and we are now at the forefront of SA becoming a recognized global leader in hemp and cannabis production. To further these efforts, last week I attended the AFASA AGM conference and gave a presentation to 1000’s of farmers who are now part of the Cannabis Commodity Cluster Formation, which I’ve been appointed as National Cannabis Commodity Chairman – The first in history.” (link to Dr.J Cannabis Expo 2022 presentation discussing SA community uplift and cannabis: youtube.com/DR.J ) Dylon Du Plooy, Protext CEO, commented, “The hemp renaissance is well underway, with renewed interest from global industrial companies to find cheaper and greener resources that can be used to produce 1000’s of end product. America is decades behind the sustainable materials revolution. That represents a big opportunity for us to unlock the potential of industrial hemp in the world’s strongest economy, with the lowest cost product available globally. For South Africa, the opportunity is to take a global role in what we believe is the beginning of an industrial hemp renaissance. We can not only produce product at the lowest cost basis on a global basis, but we can monetize the farm with 3 annual grows, making our hemp, biomass, and cannabis much sought after from customers around the world. In fact, this substantial off take agreement for an initial 2.3 m illion pounds is being delivered to a US customer. Why? Not only for the quality of the product, but our cost basis is so competitive we can deliver product that includes freight shipping cost to US customers, that is lower than they can get anywhere in North America.” #TXTMTribe #TXTMTribeRaok #TXTMRaok. Dr. J continued, “As we have previously discussed, we believe there is significant value in the human capital derived from our knowledge, Government and other relationships, compliance, resources, facilities, biomass, and infrastructure that is invaluable. The Permits we are in possession of allow for Genus Cannabis Sativa import, export, grow & cultivation, research, testing, and end product development for global distribution, all of which are anticipated to be utilized by Protext with the end goal to commercialize the live plant extraction technology and bring superior end products to the global market. Having technology that’s been tested and proven to increased bioavailability by 10-15x is significant and puts us miles ahead of all competitors. Additional testing is anticipated to be conducted with cannabis being grown on the farm right now. The testing will focus on maximizing yield as well as testing various strains of Genus Cannabis Sativa. We will also begin conducting the R&D using the New Age Extraction Technology for other Indigenous Plant Flora with medicinal properties including Psilocybin. We believe that the significance of the implications our live plant Extraction Technology can have on not only our yield, but also on an entire industry with its 10-15X Bioavailability has been over looked due to the complexity of the science. In layman’s terms we stand to produce Natural Plant Based Medicine with 10-15 times more bioavailability than current products on the market, at a fraction of the cost. “As we previously discussed, but worth repeating, we entered into this transaction with Protext as we believe there to be numerous synergies by allowing access to certain assets of our established business’ with Protext as well as commercialize the Protext proprietary live plant extraction technology and processes into our existing Genus Cannabis Sativa infrastructure. Prior to the merger, Protext had collaborated with RSAMMD whereby the companies utilized Protext’s proprietary live plant extraction technology along with Kettle extraction equipment to conduct a series of live cannabis extraction testing at New Castle Farm under permits for Genus Cannabis Sativa, with the goal to produce an emulsion rich with cannabinoid but with little to no conversion of THC-A to psychoactive THC. We undertook a series of tests to prove out that the Kettle system and extraction technologies did what they were supposed to do. As part of our previous investigations, various tests were completed using live cannabis flower and leaf, rendered into liquid emulsions supplied by the farm in New Castle. Prior to now, it was hypothecated that processing live Genus Cannabis Sativa under lower temperatures would yield a rich nano-emulsion of phytocannabinoids while retaining the non-psychoactive precursor acid form (THC-A). Our investigations have conclusively demonstrated that full-spectrum cannabinoids can be extracted using the proprietary Kettle system, with minimal metabolic conversion, paving the way for advancement of medical research using non-psychoactive cannabis. What has also intrigued us are the findings from prior research and clinical trials that have shown that the Kettle system, when applied to other medicinal plants, can create an extract that is significantly more bioavailable (10-15x) than a standard extract. This means that our cannabis extract should be more potent while providing a dose that could potentially last up to 24 hours in the bloodstream, which is in-line with prior clinical results using other medicinal plants. Medically, this opens the door to a line of natural pharmaceuticals derived from cannabis but at a fraction of the price and with potentially superior outcomes. From a business perspective, an increase of bioavailability in that magnitude can be a game changer for cultivators as it essentially could increase the net yield by a factor of 10-15x per plant, per acre, per farm. This initial order is just the beginning and leadership is excited for what’s to come. We will lead the change we want to see in our world” concluded Dr.J. CONTACT INFORMATION For further information, or inquiries relating to partnerships in SA, JV opportunities and/or off-take/supply agreements please feel free to contact us Dylon Du Plooy at: dylon@rsammd.co.za Dr.J at: exportintl@aol.com Follow us at: https://twitter.com/RSAMMD https://twitter.com/ProtextP About Protext (OTC PINK: TXTM) Through its prior acquisitions, Protext has engaged in the research, testing and development of highly bioavailable botanical products all-natural ingredients formulated for nutraceutical and pharmaceutical applications through the use of proprietary live plant extraction technology. Website: www.protxtm.com About RSAMMDA.LLC: RSAMMDA.LLC. is a wholly owned subsidiary of TXTM focused on acquisitions with two principals, Mr. Dylon Du Plooy and Dr. Ahmed Jamaloodeen (“Dr. J”). Mr. Du Plooy is a South African pioneer in the research, cultivation, production and distribution of medical cannabis and cannabinoids. Dr. J operates the 5000 Hectare New Castle Farm as well as federally issued hemp permits issued by the Government of South Africa. Together, we partner with leading hospitals and universities globally to advance the clinical benefits and applications of cannabinoids. RSAMMDA.LLC founders are a group of medical doctors and pharmacists, and cannabis activists who have been at the forefront of medical cannabis legislation and South African cannabis legalization, which took place in September 2018. We are committed to the advancement of technology and scientific research that leads to an improved quality of life for patients around the world. Website: www.rsammda.com Safe Harbor Statement This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward- looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward- looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. The company disclaims any obligation to update information contained in any forward-looking statement. This press release shall not be deemed a general solicitation. Contact Details Dylon Du Plooy +27 72 889 2581 dylon@rsammd.co.za Company Website https://www.protxtm.com/

November 01, 2022 02:57 PM Eastern Daylight Time

Article thumbnail News Release

AmeriLife Welcomes Southern Life Insurance Group to its Growing Distribution Network

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions, announced today that it has partnered with Southern Life Insurance Group. Southern Life Insurance Group, under the leadership of founders and owners Crystal and Nicholas Poe, is an independent marketing organization (IMO) with a legacy of training service-oriented agents and advisors to deliver on the holistic health and financial needs of their clients. Per the agreement, terms of the deal were not disclosed. "Today represents a watershed moment in the history of Southern Life Insurance Group,” said Crystal and Nicholas Poe in a joint statement. “We believe that in order to reach your potential, you should surround yourself with great, trustworthy leaders who hold you accountable and push you to new heights. We’re proud to call many at AmeriLife our friends and mentors, and excited for the future that we’ll build – together – on behalf of our agents and clients." Headquartered in LaGrange, Ga., Southern Life Insurance Group offers competitive life insurance and final expense products as well as annuities, Medicare Advantage and Medicare Supplement solutions, and mortgage protection to beneficiaries across the Southeast as well as in Texas and Michigan. The company has built a strong reputation through its rigorous, four-week development program for new and experienced agents that emphasizes – in equal measures – mentorship, client relationship building, and in-depth product training. Now, with access to AmeriLife’s best-in-class technology, resources and distribution leadership, Southern Life Insurance Group is well positioned to accelerate its nationwide expansion efforts. “I’m pleased to welcome Crystal, Nicholas and the Southern Life Insurance Group family to ours,” said Mike Vietri, AmeriLife’s Chief Distribution Officer. “Their mission, values and approach on training agents, with a holistic perspective on their clients’ needs, is perfectly aligned with AmeriLife’s vision for the future of distribution. Their potential is limitless, and we look forward to helping Southern Life Insurance Group succeed and grow.” ### About Southern Life Insurance Group Southern Life Insurance Group has an unwavering commitment to providing the best personal service possible. We are responsive, offer quality products with solid financial backing by A-rated companies, helpful, friendly associates with extensive knowledge and experience. Our valued clients and their family members can rely on us to be there if and when they need us. We take these obligations very seriously. Everything we do is focused on fulfilling our commitments. As your “agent for life,” we genuinely want you to have the best experience possible every time you deal with Southern Life. For more information, visit SouthernLifeIns.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

November 01, 2022 01:00 PM Eastern Daylight Time

Article thumbnail News Release

FORGOTTEN MOM LAUNCHES CAPITAL CAMPAIGN FOCUSING ON MOTHERS WITH ADDICTION, A DRAMATICALLY UNDERSERVED POPULATION

Forgotten Mom Inc.

In an effort to improve outcomes and better support mothers struggling with addiction, a capital campaign for Forgotten Moms is launching today in Florida. According to data collected by the National Institute of Health (NIH), 22M Americans struggle with addiction, 23M are in addiction recovery, and 45M are directly impacted by addiction. Of those checking into treatment centers, 32% are mothers. Additionally, these women need inpatient and outpatient treatment, as well as housing to keep families together and mothers supported. Historically, many women are pushed through the court system on drug charges, where they may end up in jail, separated from their children, with many children going into foster care. Dr. Anita Cocoves, from the Critical Incident Stress Management Team of the Treasure Coast in Florida says, “As we continue to see issues with the opioid epidemic and treatment, women continue to be homeless, without care, and emotionally hopeless. They desperately need treatment, education, and longer-term support to stay healthy.” Farid Dallal, Advisor to NueroPsychiatric Addiction Treatment of Port St. Lucie, Florida, has been underwriting treatment for the last five years with his own money and has spent close to $200,000 providing scholarships for treatment service and access to over 500 people. In 2016, he created the charity, non-profit Forgotten Mom, and is now raising funds to build out a new treatment and housing facility, along with longer-term resource and education supports. Dallal says, “In the past two years, we have lost three non-profits in the South Florida area who have served these women. There is nothing for them. They need a place that is safe, trustworthy, and somewhere to keep their families together. We will be providing longer term educational support as well, to prevent relapse.” The Forgotten Mom Capital Campaign seeks to raise $2.68M and will run through 2023 with a fundraiser and documentary film in development now. They continue to build awareness and services regionally, nationally, and internationally for this necessary treatment. Adriana Cottet, lead coordinator of the capital campaign, adds, “We invite everyone to donate to this critically underserved population. Our goal is to expand our services through this capital campaign and continue to serve more women and their families.” For more information, see www.forgottenmoms.org or info@forgottenmoms.org About Forgotten Mom: Forgotten Mom Inc. (FMI), is a registered (501(c)(3), non-profit initiative established in 2016 to address, support, and find help for the dramatically underserved population of mothers struggling with the disease of addiction. www.forgottenmoms.org Contact Details Farid Dallal +1 646-640-6099 info@forgottenmoms.org Company Website http://www.forgottenmoms.org

November 01, 2022 11:11 AM Eastern Daylight Time

Article thumbnail News Release

Former Fortune 500 Healthcare Executive Joins AliMed, Inc., As Senior Vice President Of Commercial Growth And Development

AliMed, Inc.

AliMed, Inc., a Massachusetts-based medical supply manufacturer and distributor, announced today that Jeff Hastings has joined its Senior Leadership Team as the Senior Vice President of Commercial Growth and Development. In his new role, Hastings will lead AliMed’s national sales and sales support teams, spearheading commercial expansion of its product portfolio to strengthen the company’s position and market share in both the acute and post-acute care space. Additionally, Hastings will drive efforts to develop and execute programs with preferred suppliers, build on core contract positions within the GPO, federal government, and healthcare-provider segments, and enhance the customer experience. “Jeff has relentlessly proven over his more than 20 years in healthcare leadership to be a key cog in some very critical and highly strategic endeavors,” said Adam S. Epstein, CEO of AliMed. “He is superbly skilled at developing and leading high-performing sales teams with a track record for elevating companies to the next level. We are very excited to welcome Jeff and his talents to our team.” As an influential senior executive in the healthcare industry, Hastings brings decades of leadership experience to AliMed. He has led major corporate initiatives focused on strategic transformation, portfolio diversification, and revenue acceleration for long-term sustainability at some of the nation’s largest healthcare organizations, including Owens and Minor, Cardinal Health, Hill-Rom, Roche Diagnostics, and Vizient (formerly MedAssets). Most recently, Hastings was operating partner at Mountain Pacific Fund, a life sciences investment firm based in Salt Lake City. “AliMed has such a rich, mature, and robust foundation to build on,” Hastings said of AliMed’s more than 50 years in the medical products space. “There is a great sense of enormity in this opportunity, and I’m thrilled—with the support of Adam and a very dedicated AliMed team—to help bring this organization to new heights.” A native of Ohio, Hastings holds a master’s degree in Education from the University of Akron and a bachelor’s degree in Sports Medicine and Health Education from Ashland University. About AliMed AliMed, Inc. manufactures and distributes acute and post-acute medical products and devices. For over 50 years, AliMed has innovated to deliver flexible supply chain solutions with superior service and value-based products focused on the safety and productivity of the healthcare community. AliMed’s broad portfolio of products for domestic and international care providers, dealers, and distributors are designed to improve patient outcomes and experiences from “hospital to home.” Contact Details Amy Fontaine Marketing Communications +1 857-205-8264 afontaine@alimed.com Company Website https://www.alimed.com/

November 01, 2022 10:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Black Women, Breast Cancer and the Tests That Can Save Lives

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/13nWSPuDIAs The death rate from breast cancer continues to decline, according to a new report from the American Cancer Society. But there's a wide, worrisome gap in Black women's outcomes that remains unchanged. Black women are more likely to die from breast cancer than white women. While breast cancer incidence rates among Black and white women are close, mortality rates are markedly different, with Black women having a 41% higher death rate from breast cancer. Black women are disproportionally affected by more aggressive breast cancers because of their biology. A recent study showed that Black women are significantly more likely to have genomically High Risk tumors compared to white women, despite having the same clinical factors. This means that, all other things the same – right down to their age and the size of their tumors – the Black women in the study were more likely to have a more aggressive type of cancer. The way we can address some of these disparities is through genomic tests like MammaPrint and BluePrint, which look at 150 important genes within a tumor to estimate the risk of recurrence of that cancer. The number of genes/RNA analyzed by MammaPrint and BluePrint is higher than any other test, and captures the diversity of pathways that allows for consistent results regardless of race and ethnicity. With that information, we as physicians can make more informed decisions with our patients about what their optimal treatment plan should be. There are a few available genomic tests utilized in the clinic to guide discussions around chemotherapy benefit. One example is MammaPrint/BluePrint which are the most comprehensive tests with the most consistent results across diverse groups of patients, compared to other tests. In addition, only the BluePrint test can catch tumor subtypes that may look less dangerous, but actually behave more like triple negative breast cancer when you further classify. This is a very aggressive kind of cancer, that is over-represented among Black women. It is very important the gene expression profiling result a woman receives about her tumor is consistent and reliable regardless of her ethnicity and race, like MammaPrint and BluePrint’s. Studies showing mis-categorization of risk in minority populations due to under-representation of these patients in genomic studies and clinical trials that lead to the approval of these tests is alarming. Every woman with breast cancer has the right to know the correct and clear biological information from her tumor, regardless of her skin color, so she can make timely decisions about her treatment with her care team. For more information about gene expression profiling, including resources that can help you talk to your doctor to make sure the test being offered will work best and most accurately for you, go to Agendia.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 01, 2022 10:00 AM Eastern Daylight Time

Video
Article thumbnail News Release

The Chicago School of Professional Psychology Produces 'Change Makers'

The Chicago School of Professional Psychology

The next generation of mental health professionals - some 275 “change makers” were awarded master’s and doctoral degrees last Friday at two commencement ceremonies for the Washington, DC campus of The Chicago School of Professional Psychology. The graduates enter a profession dealing with severe shortages at a time when experts say as many as one-in-five people in this country suffer from a mental disorder, and only half of those who need help can get it. In addressing the graduates, Dr. Michele Nealon, Psy.D. President of The Chicago School, said “I hope that your time as a Chicago School student has lit a fire within you – a fire to provide empathetic support for those in need. I urge you to follow your passion for service as far as you can and to light the way for others.” Joining Dr. Nealon in awarding diplomas was Dr. Donald Schultz, Ph.D, Chief Academic Officer of The Chicago School and Dr. Thelma Day, Ph.D., recipient of an honorary degree for her contributions as a counselor-educator, organizational leader and college professor. One of two student speakers was Dr. Akshaya Parthasarathi, Ph.D., a data analyst at the federal Office of Minorities and Women Inclusion, tasked by the U.S. Congress to develop policies to ensure equitable treatment of all by the nation’s financial institutions. She shared her story as an international student who is grateful to her professors and fellow students. “What looked like a distant dream for a girl from India, to study abroad in an institution like this, was made possible because of each of you. Accepting me as I am--allowing me to be different--has let me grow into a global citizen with varied experiences and stories in my pocket,” she said. “My goal is to share these experiences with people of the world, to show the power of community, and the success one can achieve when people let you be you.” Another student speaker, Dr. Bethany Patterson, Ph.D., serves as clinical director at Helianthus Positive Behavior Supports, provider of counseling services to children and families in Virginia and North Carolina. She told her story, as she sought an institution that would support her role as a military spouse and mother of three. “I needed a school that was supportive and respectful of the military lifestyle because I had unique needs,” she said. “I found a place where the learning environment is optimized by active learners with diverse cultures,” she said. “Today I embody The Chicago School’s values of innovation, service, and community-- I am giving back by creating a space to encourage other military spouses to further their education.” The Chicago School serves a majority minority student body in which two of three students identify as individuals of color. The 43-year old non-profit institution has more than 6,000 students enrolled in 30 degree and certificate programs. About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details Vivien Hao +1 323-893-4743 vhao@thechicagoschool.edu

November 01, 2022 06:00 AM Pacific Daylight Time

Article thumbnail News Release

VectorBuilder Raised $57 Million for Gene Delivery R&D

VectorBuilder Inc.

VectorBuilder Inc. – a global leader in gene delivery technologies – recently announced the completion of $57 million funding, which was co-led by Legend Capital. The fund will support the construction of VectorBuilder’s new Gene Delivery Research and Manufacturing Campus, and further boost the company’s R&D capabilities and global business presence. VectorBuilder was initially established in 2014 to commercialize its novel e-commerce platform that enabled researchers to design and order custom vectors online. This award-winning platform quickly gained popularity and propelled VectorBuilder to grow at an explosive pace in the ensuing years. Now VectorBuilder has become a leading provider of gene delivery solutions for both basic research and genetic medicine, and offers a full spectrum of CRO, CDMO and IP out-licensing services. VectorBuilder operates as a multinational company with branches in North America, Europe, China, Japan, South Korea, Israel and Australia, and has over 50,000 customers from over 4,000 organizations in over 80 countries around the world. VectorBuilder’s CDMO products have entered IND in many countries and received approval from the FDA and other regulatory authorities. Dr. Bruce Lahn, Chief Scientist of VectorBuilder, commented: "The fund will significantly speed up the construction of our 100,000 square meter Gene Delivery Research and Manufacturing Campus that was launched in April this year. It will also boost several major R&D projects we have undertaken such as the AAV Superbank initiative. With this funding, we can go full throttle in developing innovative gene delivery technologies that will make research more efficient, and genetic medicine more effective and affordable." About VectorBuilder Inc. VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Design Studio is a transformative innovation that allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions including advanced AAV capsid engineering capabilities, and state-of-the-art GMP facilities. With leading R&D and CDMO manufacturing capacity, the VectorBuilder team strives to provide the most effective gene delivery solutions and develop new tools for life sciences research and genetic medicine. Contact Details VectorBuilder VectorBuilder PR +1 800-517-2189 outreach@vectorbuilder.com

November 01, 2022 08:00 AM Central Daylight Time

Image
Article thumbnail News Release

PsyKey, Inc. Announces Veteran Corporate Executive & Scientific Innovator John Gustin as Head of Global Business Development

CeCors, Inc.

CECORS, INC. (OTC PINK: CEOS) ("CeCors" or the "Company"), through its wholly owned subsidiary PsyKey Inc. an innovative wellness company, is pleased to announce the appointment of John Gustin as head of global business development. John Gustin is a veteran corporate executive and scientific innovator with more than three decades of experience building some of the fastest growing nutritional companies and brands in direct sales. Moreover, Gustin has led the effort to develop and patent numerous successful formulations for functional health and wellness products, and has authored numerous published articles related to immunology, diabetes, obesity and sports nutrition. One such patent, “# 5,914,326 Method for Promoting Weight and Fat Loss” was licensed to the former US Surgeon General Dr. C. Everett Koop. “Having John join and help guide the company, will not only give us an immense competitive advantage from a business standpoint, it opens the doors to true science backed progression and novel technologies,” said Amar Bhatal, PsyKey co-founder and president. “John’s extensive nutraceutical background, key relationships, business acumen, and his product development skills will help PsyKey strengthen existing and developing partnerships, advance strategic alliances, and expand our overall footprint in the U.S. and internationally.” “I am very excited to be joining the PsyKey team,” said Gustin. “I believe the company has a great business model and talented management team uniquely positioned to capitalize on the evolving functional wellness industry. As the industry evolves, PsyKey is poised to make a significant impact in the functional wellness market by providing a timely and cost-effective suite of brands to help consumers lead healthier, more optimized lives and routines.” As a consultant Gustin played a prominent role in the growth of numerous direct market giants, such as Nikken, Isotonix and NuSkin, providing guidance in product development and marketing strategies. He is generally credited with introducing the fat-burning, staple supplement Garcinia Cambogia to the U.S. market and helped to conduct the first human clinical studies. As a corporate member of United Sciences of America, Inc., Gustin helped the direct market company become the second fastest growing corporation in history with over $100 million in sales in its first nine months of operation. Gustin was also a founder and key executive of Evolv Health, LLC, makers of science-based functional beverages, which realized annual revenues exceeding $80 million. His discoveries and the brands he has helped develop have been viewed by millions on CNN, NBC, CBS, ABC and Fox news. About PsyKey, Inc. PsyKey, Inc. is an innovative wellness company that specializes in the development and commercialization of mycology-based entheogenic, adaptogenic, and nootropic ingredients and formulations. From functional to medicinal PsyKey, Inc. believes in the magic of mushrooms. As part of its optimal wellness strategy, PsyKey understands the importance of access to support services and healthcare professionals. Management is continuously engaged in the development of tools that will aid in removing barriers and providing inclusivity. For further information: (OTC Pink: CEOS) www.psykeyworld.com E-mail: info@psykeyworld.com Follow us on Twitter: https://twitter.com/PsyKeyworld Forward-Looking Statements: Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward- looking statements. Contact Details Sukhinderpaul Kalsi info@psykeyworld.com Company Website https://psykeyworld.com/

October 31, 2022 02:11 PM Eastern Daylight Time

Article thumbnail News Release

This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers

Can-Fite Biopharma

The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up. Psoriasis is a chronic inflammatory skin disease caused by genetic disposition or environmental factors and is a burgeoning $16 billion global market, according to Prophecy Market Insights. Pharmaceutical companies are racing to develop new proprietary psoriasis pill options. Bristol-Myers Squibb Co. (NYSE: BMY) just saw its stock soar on news of FDA approval of oral Sotykty, joining Amgen Inc. ’s (NASDAQ: AMGN) Otezla which has been the dominant oral pill for psoriasis. But in addition to the expense of injectables and pills used to bring relief to people living with psoriasis, some of the pill options have so many side effects that many people have decided they aren’t worth ingesting. Can-Fite’s Piclidenoson Shows Positive Trial Results Another biotechnology company developing its own proprietary small-molecule drugs has presented new positive data from its Phase III COMFORT study that its Piclidenoson drug has shown a “statistically significant improvement over placebo in psoriasis patients.” Dr. Kim A. Papp, a world-renowned dermatologist, presented the news from Israel-based Can-Fite BioPharma Ltd. (NYSE American: CANF) at the 31st European Academy of Dermatology and Venerology Congress. The company reports that Piclidenoson is now advancing into a Phase III psoriasis registration trial. Developed by Papp, the protocol will be submitted this year to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for market clearance. Can-Fite is an advanced clinical-stage drug development company with a pipeline of proprietary drugs designed to help multibillion-dollar markets in treating inflammatory, cancer and liver diseases. Among its Piclidensoson drug study findings, Can-Fite reported: Its COMFORT Phase III study met its primary endpoint of superiority versus placebo at 16 weeks Patients treated with Piclidenoson showed an improving progressive response over time Piclidenoson demonstrated an excellent safety profile, overlapping the placebo-treated group. Piclidenoson, a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule drug which is orally bioavailable, has an excellent safety profile demonstrating evidence of efficacy in Phase II clinical studies, according to Can-Fite. "The safety results on Piclidenoson and its progressive effectiveness over the study period position it as unique among the current treatment options — especially given the chronic nature of psoriasis, which can necessitate long-term treatment,” Papp said. Piclidenoson Versus Otezla The Can-Fite study also found the discontinuation rate by patients taking Amgen’s Otezla was significantly higher than for Piclidenoson, based on what the company referred to as “a significantly better safety profile than Otezla including gastro intestinal-related adverse events that were only 1% for patients on Piclidenoson versus 6% for those on Otezla.” Nervous system disorders were also found to be 0.7% for people taking Piclidenoson compared to 3.3% for patients taking placebo and nearly 10% for those on Otezla. In the study, Piclidenoson demonstrated a favorable safety profile, showing results were better than the placebo-treated group, as 25.5% of patients treated with placebo had a treatment-emergent adverse event compared to only 14.8% of patients treated with Piclidenoson. The primary objective of the Can-Fite study was to evaluate the efficacy of oral Piclidenoson 2 mg or 3 mg twice daily in patients with moderate-to-severe plaque psoriasis compared with a placebo. Based on the results, analysts have set new price targets for Can-Fite, including Alliance Global Partners ($8.25), CG Capital ($6) and Dawson James Securities and H.C. Wainwright & Co. ($5). For more information on Can-Fite BioPharma, visit www.canfite.com. About Can-Fite BioPharma Ltd.Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH), and enrollment is expected to commence in a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Forward-Looking StatementsThis press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are "forward looking statements". Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to the COVID-19 pandemic and the Russian invasion of Ukraine; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the "Risk Factors" section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 24, 2022 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contact Details Motti Farbstein Motti@canfite.co.il Company Website https://www.canfite.com

October 31, 2022 09:15 AM Eastern Daylight Time

1 ... 193194195196197 ... 304